The CRISPR/Cas9 system has been extensively used to engineer genetic loci for the generation of knockouts, insertions, and point mutations in animal models. However, many mutations that have been reported in animals a...The CRISPR/Cas9 system has been extensively used to engineer genetic loci for the generation of knockouts, insertions, and point mutations in animal models. However, many mutations that have been reported in animals are small insertions or deletions. This study used the CRISPR/Cas9 system to induce large DNA fragment deletions in MSTN via three guide RNAs in sheep. This successfully achieved the precise gene editing of the ovine MSTN gene by injecting both Cas9 m RNA and sg RNAs into embryos at the one-cell stage. Of 10 edited animals, 3 animals(30%) exhibited large genomic fragment deletions(~5 kb). Furthermore, the body weights of these 3 animals were significantly different(P0<0.0001, P15=0.001, P30=0.005, P60=0.027) between lambs with large deletions and wildtype lambs. In addition, the edited lambs were also significantly different(P0<0.0001, P15<0.0001, P30=0.002, P60=0.011) compared with wildtype. These results suggest that the generated MSTN knockout sheep is a reliable and effective animal model for further study. Furthermore, this method is time-and labor-saving, and efficient for the creation of animal models for agriculture, biology, and medicine.展开更多
目的探讨血清异常凝血酶原(prothrombin induced by vitamin K absence-Ⅱ,PIVKA-Ⅱ)检测对乙型肝炎病毒(hepatitis B virus,HBV)相关肝细胞癌(hepatocellular carcinoma,HCC)生物学特性的预测价值。方法回顾性纳入2017年6月—2018年12...目的探讨血清异常凝血酶原(prothrombin induced by vitamin K absence-Ⅱ,PIVKA-Ⅱ)检测对乙型肝炎病毒(hepatitis B virus,HBV)相关肝细胞癌(hepatocellular carcinoma,HCC)生物学特性的预测价值。方法回顾性纳入2017年6月—2018年12月在四川大学华西医院新近诊断并接受手术切除治疗的HBV相关HCC患者394例。从病历中收集肿瘤大小、肿瘤数目、肿瘤细胞分化程度、有无微血管浸润、有无远处转移、有无门静脉癌栓等临床信息;收集患者诊断时和手术前实验室检查结果,包括甲胎蛋白、PIVKA-Ⅱ、谷丙转氨酶、谷草转氨酶、γ-谷氨酰转肽酶等,分析PIVKA-Ⅱ水平与肿瘤生物学特性间的关系。非正态分布资料采用中位数(下四分位数,上四分位数)表示。结果与术前低血清PIVKA-Ⅱ水平(≤40 mAU/mL)的HCC患者相比,术前高血清PIVKA-Ⅱ水平(>40 mAU/mL)的HCC患者肿瘤直径更大[5.00(3.00,9.00)vs.2.50(1.63,4.95)cm,P<0.001],更容易形成门静脉癌栓(16.61%vs.3.75%,P=0.003)和微血管浸润(43.67%vs.11.11%,P<0.001),巴塞罗那临床肝癌(Barcelona Clinic Liver Cancer,BCLC)分期更严重(P<0.001),且甲胎蛋白[186.05(6.86,1210.00)vs.17.83(4.33,231.95)ng/mL,P<0.001]、谷丙转氨酶[38.00(26.00,66.25)vs.32.00(22.00,51.00)U/L,P=0.018]、谷草转氨酶[42.00(30.00,76.00)vs.34.00(25.50,48.25)U/L,P<0.001]、γ-谷氨酰转肽酶[71.00(39.00,165.50)vs.55.50(25.00,93.00)U/L,P=0.005]水平更高。BCLC分期0期的HCC患者,PIVKA-Ⅱ阳性率仅为51.35%。多因素logistic回归分析显示,PIVKA-Ⅱ>40 mAU/mL是微血管浸润的独立预测因子[比值比=6.588,95%置信区间(1.645,26.383),P=0.008],且PIVKA-Ⅱ水平预测微血管浸润的受试者工作特征曲线下面积为0.761[95%置信区间(0.693,0.830)],灵敏度为66.22%,特异度为79.06%。结论在HBV相关HCC患者,高PIVKA-Ⅱ水平与不良的肿瘤生物学特性有关,并且是肿瘤微血管浸润的独立危险因素。展开更多
目的 探讨甲胎蛋白(alpha-fetoprotein,AFP)、甲胎蛋白异质体(alpha-fetoprotein-L3,AFP-L3)和异常凝血酶原(prothrombin induced by vitamin K absence-Ⅱ,PIVKA-Ⅱ)在肝癌诊断中的临床应用价值。方法收集2013年在我院确诊的乙型肝炎...目的 探讨甲胎蛋白(alpha-fetoprotein,AFP)、甲胎蛋白异质体(alpha-fetoprotein-L3,AFP-L3)和异常凝血酶原(prothrombin induced by vitamin K absence-Ⅱ,PIVKA-Ⅱ)在肝癌诊断中的临床应用价值。方法收集2013年在我院确诊的乙型肝炎、肝硬化和肝癌的住院患者血清235例。其中良性肝病组包括乙型肝炎及肝硬化共计150例,肝细胞癌组85例。应用微量离心柱法分离血清AFP-L3,应用电化学发光免疫分析仪检测AFP及AFP-L3含量,应用酶免疫发光分析仪检测PIVKA-Ⅱ含量。结果良性肝病组的AFP及PIVKA-Ⅱ水平均低于肝细胞癌组,其中AFP、PIVKA-Ⅱ在肝细胞癌组与良性肝病组之间均差异存在统计学意义(P<0.001)。ROC分析显示,AFP、PIVKA-Ⅱ及AFP-L3的AUC分别为0.712、0.755和0.513。当AFP临界值为20ng/ml时,灵敏度为61.2%,特异性为74%;当PIVKA-Ⅱ临界值为62.5AU/ml时,灵敏度为58.8%,特异性为82.6%;当AFP-L3比值临界值为10%时,灵敏度为47.7%,特异性为66.7%。血清PIVKA-Ⅱ和AFP浓度与肿瘤体积的秩相关系数分别为0.395和0.244(P值分别为<0.001和0.03)。结论PIVKA-Ⅱ较AFP及AFP-L3能提供更好的诊断效能,PIVKA-Ⅱ应用于肝细胞癌诊断可提供更高的实验诊断特异度,同时能提供与疾病相关的更有价值的信息用于临床评估。展开更多
基金supported by the grants from the National Natural Science Foundation of China(31572369,31772571,31872332)the earmarked fund for China Agriculture Research System(CARS-39-12)the Tan Sheep Breeding Project of Ningxia,China(NXTS201601)。
文摘The CRISPR/Cas9 system has been extensively used to engineer genetic loci for the generation of knockouts, insertions, and point mutations in animal models. However, many mutations that have been reported in animals are small insertions or deletions. This study used the CRISPR/Cas9 system to induce large DNA fragment deletions in MSTN via three guide RNAs in sheep. This successfully achieved the precise gene editing of the ovine MSTN gene by injecting both Cas9 m RNA and sg RNAs into embryos at the one-cell stage. Of 10 edited animals, 3 animals(30%) exhibited large genomic fragment deletions(~5 kb). Furthermore, the body weights of these 3 animals were significantly different(P0<0.0001, P15=0.001, P30=0.005, P60=0.027) between lambs with large deletions and wildtype lambs. In addition, the edited lambs were also significantly different(P0<0.0001, P15<0.0001, P30=0.002, P60=0.011) compared with wildtype. These results suggest that the generated MSTN knockout sheep is a reliable and effective animal model for further study. Furthermore, this method is time-and labor-saving, and efficient for the creation of animal models for agriculture, biology, and medicine.
文摘目的探讨血清异常凝血酶原(prothrombin induced by vitamin K absence-Ⅱ,PIVKA-Ⅱ)检测对乙型肝炎病毒(hepatitis B virus,HBV)相关肝细胞癌(hepatocellular carcinoma,HCC)生物学特性的预测价值。方法回顾性纳入2017年6月—2018年12月在四川大学华西医院新近诊断并接受手术切除治疗的HBV相关HCC患者394例。从病历中收集肿瘤大小、肿瘤数目、肿瘤细胞分化程度、有无微血管浸润、有无远处转移、有无门静脉癌栓等临床信息;收集患者诊断时和手术前实验室检查结果,包括甲胎蛋白、PIVKA-Ⅱ、谷丙转氨酶、谷草转氨酶、γ-谷氨酰转肽酶等,分析PIVKA-Ⅱ水平与肿瘤生物学特性间的关系。非正态分布资料采用中位数(下四分位数,上四分位数)表示。结果与术前低血清PIVKA-Ⅱ水平(≤40 mAU/mL)的HCC患者相比,术前高血清PIVKA-Ⅱ水平(>40 mAU/mL)的HCC患者肿瘤直径更大[5.00(3.00,9.00)vs.2.50(1.63,4.95)cm,P<0.001],更容易形成门静脉癌栓(16.61%vs.3.75%,P=0.003)和微血管浸润(43.67%vs.11.11%,P<0.001),巴塞罗那临床肝癌(Barcelona Clinic Liver Cancer,BCLC)分期更严重(P<0.001),且甲胎蛋白[186.05(6.86,1210.00)vs.17.83(4.33,231.95)ng/mL,P<0.001]、谷丙转氨酶[38.00(26.00,66.25)vs.32.00(22.00,51.00)U/L,P=0.018]、谷草转氨酶[42.00(30.00,76.00)vs.34.00(25.50,48.25)U/L,P<0.001]、γ-谷氨酰转肽酶[71.00(39.00,165.50)vs.55.50(25.00,93.00)U/L,P=0.005]水平更高。BCLC分期0期的HCC患者,PIVKA-Ⅱ阳性率仅为51.35%。多因素logistic回归分析显示,PIVKA-Ⅱ>40 mAU/mL是微血管浸润的独立预测因子[比值比=6.588,95%置信区间(1.645,26.383),P=0.008],且PIVKA-Ⅱ水平预测微血管浸润的受试者工作特征曲线下面积为0.761[95%置信区间(0.693,0.830)],灵敏度为66.22%,特异度为79.06%。结论在HBV相关HCC患者,高PIVKA-Ⅱ水平与不良的肿瘤生物学特性有关,并且是肿瘤微血管浸润的独立危险因素。
文摘目的 探讨甲胎蛋白(alpha-fetoprotein,AFP)、甲胎蛋白异质体(alpha-fetoprotein-L3,AFP-L3)和异常凝血酶原(prothrombin induced by vitamin K absence-Ⅱ,PIVKA-Ⅱ)在肝癌诊断中的临床应用价值。方法收集2013年在我院确诊的乙型肝炎、肝硬化和肝癌的住院患者血清235例。其中良性肝病组包括乙型肝炎及肝硬化共计150例,肝细胞癌组85例。应用微量离心柱法分离血清AFP-L3,应用电化学发光免疫分析仪检测AFP及AFP-L3含量,应用酶免疫发光分析仪检测PIVKA-Ⅱ含量。结果良性肝病组的AFP及PIVKA-Ⅱ水平均低于肝细胞癌组,其中AFP、PIVKA-Ⅱ在肝细胞癌组与良性肝病组之间均差异存在统计学意义(P<0.001)。ROC分析显示,AFP、PIVKA-Ⅱ及AFP-L3的AUC分别为0.712、0.755和0.513。当AFP临界值为20ng/ml时,灵敏度为61.2%,特异性为74%;当PIVKA-Ⅱ临界值为62.5AU/ml时,灵敏度为58.8%,特异性为82.6%;当AFP-L3比值临界值为10%时,灵敏度为47.7%,特异性为66.7%。血清PIVKA-Ⅱ和AFP浓度与肿瘤体积的秩相关系数分别为0.395和0.244(P值分别为<0.001和0.03)。结论PIVKA-Ⅱ较AFP及AFP-L3能提供更好的诊断效能,PIVKA-Ⅱ应用于肝细胞癌诊断可提供更高的实验诊断特异度,同时能提供与疾病相关的更有价值的信息用于临床评估。
